Abstract
Malignant gliomas are common primary tumors of the central nervous system, characterized by aggressive cell proliferation, diffuse infiltration and resistance to conventional therapy. Glioblastoma (former Glioblastoma multiforme, GBM), grade IV astrocytoma, is the most aggressive tumor, with a median survival of around 14 months. New therapies against this devastating and invariably fatal disease are needed. Stem-like cell populations have been identified in a number of malignancies including glioblastoma. These rare stem cells (called also glioma-initiating cells) are believed to be responsible not only for tumor initiation and progression but also resistance to therapeutic agents and tumor recurrence. Recently, the population of cells within glioblastoma with stem-like properties has gained increasing attention as a target to refine treatment strategies. This chapter aims to summarize the recent data regarding isolation, biology and mechanisms of resistance of glioblastoma stem-like cells to therapy.
Keywords: Glioblastoma, glioma-initiating cells (GIC), glioma stem cells (GSC), functional characteristics, isolation, markers, therapeutic resistance.
Current Signal Transduction Therapy
Title:Glioblastoma Stem-Like Cells – Isolation, Biology and Mechanisms of Chemotherapy Resistance
Volume: 8 Issue: 3
Author(s): Iwona Anna Ciechomska, Marta Kocyk and Bozena Kaminska
Affiliation:
Keywords: Glioblastoma, glioma-initiating cells (GIC), glioma stem cells (GSC), functional characteristics, isolation, markers, therapeutic resistance.
Abstract: Malignant gliomas are common primary tumors of the central nervous system, characterized by aggressive cell proliferation, diffuse infiltration and resistance to conventional therapy. Glioblastoma (former Glioblastoma multiforme, GBM), grade IV astrocytoma, is the most aggressive tumor, with a median survival of around 14 months. New therapies against this devastating and invariably fatal disease are needed. Stem-like cell populations have been identified in a number of malignancies including glioblastoma. These rare stem cells (called also glioma-initiating cells) are believed to be responsible not only for tumor initiation and progression but also resistance to therapeutic agents and tumor recurrence. Recently, the population of cells within glioblastoma with stem-like properties has gained increasing attention as a target to refine treatment strategies. This chapter aims to summarize the recent data regarding isolation, biology and mechanisms of resistance of glioblastoma stem-like cells to therapy.
Export Options
About this article
Cite this article as:
Ciechomska Anna Iwona, Kocyk Marta and Kaminska Bozena, Glioblastoma Stem-Like Cells – Isolation, Biology and Mechanisms of Chemotherapy Resistance, Current Signal Transduction Therapy 2013; 8 (3) . https://dx.doi.org/10.2174/1574362409666140206223501
DOI https://dx.doi.org/10.2174/1574362409666140206223501 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeted Drug Delivery to Central Nervous System (CNS) for the Treatment of Neurodegenerative Disorders: Trends and Advances
Central Nervous System Agents in Medicinal Chemistry Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets Regulation of Autophagy by Sphingolipids
Anti-Cancer Agents in Medicinal Chemistry In Vivo Roles of CDC25 Phosphatases: Biological Insight into the Anti-Cancer Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
Recent Patents on Biomarkers Stem Cells as In Vitro Models of Disease
Current Stem Cell Research & Therapy Editorial [Hot Topic: Immunotherapy of Cancer (Guest Editors: Ezra E.W. Cohen and Nikolai G. Rainov)]
Reviews on Recent Clinical Trials Endogenous Events Modulating Myogenic Regulation of Cerebrovascular Function
Current Vascular Pharmacology Drugging Cell Cycle Kinases in Cancer Therapy
Current Drug Targets Cucurbitacin E, An Experimental Lead Triterpenoid with Anticancer, Immunomodulatory and Novel Effects Against Degenerative Diseases. A Mini-Review
Current Topics in Medicinal Chemistry Structure of the Epidermal Growth Factor Receptor Gene and Intron Recombination in Human Gliomas
Current Genomics Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Mini-Reviews in Medicinal Chemistry Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets Radiation-Induced Stress Proteins - the Role of Heat Shock Proteins (HSP) in Anti- Tumor Responses
Current Medicinal Chemistry GRP78 Influences Chemoresistance and Prognosis in Cancer
Current Drug Targets Application of Glutathione as Anti-Oxidative and Anti-Aging Drugs
Current Drug Metabolism New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis
Current Medicinal Chemistry Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis
Current Drug Targets Adenovirus Mediated Herpes Simplex Virus-Thymidine Kinase/Ganciclovir Gene Therapy for Resectable Malignant Glioma
Current Gene Therapy